Associated Papers
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S et al.
Journal of Cancer Research and Clinical Oncology, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Castroviejo-Bermejo M et al.
Embo Molecular Medicine, 2018
30377213 (PubMed )
Supplement: EMMM-10-e9172-s006.docx
Select a paper to view details